Nabriva Therapeutics (NBRV) : positive trial of pneumonia treatment

• www.nabriva.com
• HQ: Dublin,  Ireland
• Founded in 2006
• IPO in 2015
• 59 Employees

The company reported positive results from a late-stage trial of a treatment for community-acquired bacterial pneumonia, or CABP, the leading cause of infectious death in the U.S. The Dublin, Ireland-based company said its intravenous to oral lefamulin met its primary endpoint. "These Phase 3 data provide strong evidence of the potential of lefamulin to treat adults with CABP and provide an alternative to a current gold standard treatment regimen," Nabriva Chief Executive Dr. Colin Broom said in a statement. The company is currently completing enrollment for a second phase 3 trial of the drug and expects to have topline data ready by spring of 2018. The stock has gained 15% in 2017 through Friday, while the S&P 500 (SPX) has gained about 12%.

********

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of novel antibiotics to treat serious bacterial infections with a focus on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, a novel semi-synthetic pleuromutilin antibiotic for systemic administration in humans. The company’s product, lefamulin is being studied in two registrational Phase 3 clinical trials in patients with moderate to severe community-acquired bacterial pneumonia. It is also developing lefamulin that has completed Phase 2 clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as in preclinical studies for antibacterial activity against various gram-positive bacteria, gram-negative bacteria, and atypical bacteria, including multi-drug resistant strains. In addition, the company is developing BC-7013, a topical pleuromutilin product candidate, which has completed a Phase 1 clinical trial for the treatment of various gram-positive infections, including uncomplicated skin and skin structure infections. Nabriva Therapeutics plc was founded in 2006 and is based in Dublin, Ireland.

** charts before ** 

Innocoll (INNL) began trading on the NASDAQ on 25 July 2014

The Irish drug company makes after-surgery pain treatment and medicine for diabetic foot infections. It raised $58.5 million after pricing 6.5 million American depositary shares at $9 per ADS. It previously expected to raise more money, between $69.6 million and $80.3 million, in a larger offering of shares. Innocoll plans to use the cash it raised to develop its treatments and increase its manufacturing infrastructure. Its shares, which are trading on the Nasdaq exchange under the symbol "INNL," closed flat at $9. During trading hours, the stock fell as low as $8.58 and rose as high as $9.51.